Corvus Pharmaceuticals(CRVS) - 2023 Q4 - Annual Results

EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib's potential to address the need for new treatments for PTCL Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURL ...